Oppenheimer Maintains Outperform on LHC Group

Oppenheimer is out with its report today on LHC Group LHCG, maintaining Outperform. In its report, Oppenheimer writes, "We favor home health due to its promising growth led by a shift from the institutional setting into the home. Furthermore, we believe the larger providers will lead a consolidation of this fragmented industry, especially as reimbursement visibility improves. While the SEC investigation and the Senate Finance Committee are likely to plague LHCG and the other home health stocks in the short term, we believe the long-term outlook is quite strong. As a result, we believe LHC Group is one of the most attractive stocks in our group, and we maintain our Outperform rating." Oppenheimer maintains a $36 PT on LHCG. At the time of posting, shares of LHCG were trading at $22.40, up 7.64% from Wednesday's close.